Key Takeaways
- • Welltower Inc. (WELL) trades near its 52-week high of $221.68, with the stock currently trading around $205–$210 as of late May 2026, representing a 7–8% pullback from peak levels.
- • The healthcare REIT operates a diversified portfolio of approximately 2,800 properties across senior housing, medical office, and skilled nursing/post-acute care segments, with a market capitalization of $144.95 billion.
- • Institutional investors are actively adjusting positions in WELL stock, with analyst price targets ranging from $134–$239, and the consensus 1-year target estimated at $236.30, suggesting 15% upside potential from current prices.
- • Welltower's trailing P/E ratio of 99.19 reflects elevated valuation multiples relative to earnings; however, the stock maintains a low beta of 0.82–0.83, indicating lower volatility relative to the broader market.
- • The company carries a moderate debt-to-equity ratio of 44.49% with $4.7 billion in cash on hand, supporting dividend distribution with a current yield of 1.44% and an ex-dividend date of May 13, 2026.
Summary
Welltower Inc. (ticker: WELL) continues to trade within proximity of its 52-week range as institutional investors recalibrate exposure to the healthcare real estate sector. As of May 29, 2026, the stock closed at $205.33, down $4.96 or 2.36% for the session, reflecting recent profit-taking from peak levels. The 52-week range spans from $148.60 to $221.68, positioning WELL approximately 7% below its recent high and 38% above its annual low—a range that underscores the stock's performance during a volatile period for REITs and healthcare infrastructure.
The company operates as a specialized healthcare REIT with exposure across three primary segments: senior housing communities, medical office buildings, and skilled nursing facilities with post-acute care capabilities. This diversified portfolio encompasses 2,800 in-place properties, providing revenue stability across distinct healthcare real estate verticals. Welltower's trailing twelve-month revenue reached $11.77 billion, with net income of $1.41 billion and diluted EPS of $2.07, though the elevated trailing P/E ratio of 99.19 reflects the market's current pricing relative to recent earnings.
Analyst sentiment on WELL remains constructively oriented, with a consensus buy rating and price targets clustered between $134 and $239. The one-year consensus price target of $236.30 implies approximately 15% upside from current trading levels, suggesting institutional analysts anticipate recovery or appreciation. Wells Fargo downgraded the stock from Overweight to Equal-Weight in October 2024, raising its target modestly from $134 to $135—a more cautious stance relative to broader market positioning.
From a balance sheet perspective, Welltower maintains $4.7 billion in cash and equivalents against a total debt-to-equity ratio of 44.49%, positioning leverage within moderate parameters for a healthcare-focused REIT. The company's forward dividend yield of 1.44% with a most recent ex-dividend date of May 13, 2026, continues to support total return expectations. The stock's beta of 0.82–0.83 indicates lower systematic volatility relative to the S&P 500, appealing to institutional investors seeking defensive exposure within the healthcare and real estate infrastructure complex.
The company operates as a specialized healthcare REIT with exposure across three primary segments: senior housing communities, medical office buildings, and skilled nursing facilities with post-acute care capabilities. This diversified portfolio encompasses 2,800 in-place properties, providing revenue stability across distinct healthcare real estate verticals. Welltower's trailing twelve-month revenue reached $11.77 billion, with net income of $1.41 billion and diluted EPS of $2.07, though the elevated trailing P/E ratio of 99.19 reflects the market's current pricing relative to recent earnings.
Analyst sentiment on WELL remains constructively oriented, with a consensus buy rating and price targets clustered between $134 and $239. The one-year consensus price target of $236.30 implies approximately 15% upside from current trading levels, suggesting institutional analysts anticipate recovery or appreciation. Wells Fargo downgraded the stock from Overweight to Equal-Weight in October 2024, raising its target modestly from $134 to $135—a more cautious stance relative to broader market positioning.
From a balance sheet perspective, Welltower maintains $4.7 billion in cash and equivalents against a total debt-to-equity ratio of 44.49%, positioning leverage within moderate parameters for a healthcare-focused REIT. The company's forward dividend yield of 1.44% with a most recent ex-dividend date of May 13, 2026, continues to support total return expectations. The stock's beta of 0.82–0.83 indicates lower systematic volatility relative to the S&P 500, appealing to institutional investors seeking defensive exposure within the healthcare and real estate infrastructure complex.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.